<?xml version='1.0' encoding='utf-8'?>
<document id="32017149"><sentence text="Clinical Pharmacology and Safety of Trifarotene, a First-in-Class RARγ-Selective Topical Retinoid."><entity charOffset="36-47" id="DDI-PubMed.32017149.s1.e0" text="Trifarotene" /></sentence><sentence text="Trifarotene is a new drug with retinoic acid receptor activity and selectivity for retinoic acid receptor-γ"><entity charOffset="0-11" id="DDI-PubMed.32017149.s2.e0" text="Trifarotene" /><entity charOffset="31-44" id="DDI-PubMed.32017149.s2.e1" text="retinoic acid" /><entity charOffset="83-96" id="DDI-PubMed.32017149.s2.e2" text="retinoic acid" /><pair ddi="false" e1="DDI-PubMed.32017149.s2.e0" e2="DDI-PubMed.32017149.s2.e0" /><pair ddi="false" e1="DDI-PubMed.32017149.s2.e0" e2="DDI-PubMed.32017149.s2.e1" /><pair ddi="false" e1="DDI-PubMed.32017149.s2.e0" e2="DDI-PubMed.32017149.s2.e2" /><pair ddi="false" e1="DDI-PubMed.32017149.s2.e1" e2="DDI-PubMed.32017149.s2.e1" /><pair ddi="false" e1="DDI-PubMed.32017149.s2.e1" e2="DDI-PubMed.32017149.s2.e2" /></sentence><sentence text=" The reported studies aimed at assessing the clinical pharmacology and safety of trifarotene"><entity charOffset="81-92" id="DDI-PubMed.32017149.s3.e0" text="trifarotene" /></sentence><sentence text=" The clinical pharmacology of topical trifarotene up to 100 µg/g was extensively investigated through 2 maximal usage pharmacokinetic trials (MUsT) conducted in adult (≥18 years) and pediatric patients (9-17 years) with moderate to severe acne and two studies conducted in healthy volunteers: 1 thorough QTC study and 1 drug-drug interaction study with concomitantly administered oral levonorgestrel (0"><entity charOffset="38-49" id="DDI-PubMed.32017149.s4.e0" text="trifarotene" /><entity charOffset="385-399" id="DDI-PubMed.32017149.s4.e1" text="levonorgestrel" /><pair ddi="false" e1="DDI-PubMed.32017149.s4.e0" e2="DDI-PubMed.32017149.s4.e0" /><pair ddi="false" e1="DDI-PubMed.32017149.s4.e0" e2="DDI-PubMed.32017149.s4.e1" /></sentence><sentence text="15 mg)/ethinyl estradiol (0"><entity charOffset="7-24" id="DDI-PubMed.32017149.s5.e0" text="ethinyl estradiol" /></sentence><sentence text="03 mg)" /><sentence text=" Safety assessments included adverse event reporting and assessment of erythema, scaling, dryness, and stinging/burning using a scale from 0 = none to 4 = severe, as well as the evaluation of the systemic safety of trifarotene through routine laboratory testing"><entity charOffset="215-226" id="DDI-PubMed.32017149.s7.e0" text="trifarotene" /></sentence><sentence text=" Systemic absorption of trifarotene was generally unquantifiable in the target population, especially when applied at 50 µg/g"><entity charOffset="24-35" id="DDI-PubMed.32017149.s8.e0" text="trifarotene" /></sentence><sentence text=" QTC investigations did not show any risk of cardiovascular health issues; trifarotene did not reduce the systemic exposure to oral contraceptives such as levonorgestrel/ethinyl estradiol"><entity charOffset="75-86" id="DDI-PubMed.32017149.s9.e0" text="trifarotene" /><entity charOffset="155-169" id="DDI-PubMed.32017149.s9.e1" text="levonorgestrel" /><entity charOffset="170-187" id="DDI-PubMed.32017149.s9.e2" text="ethinyl estradiol" /><pair ddi="false" e1="DDI-PubMed.32017149.s9.e0" e2="DDI-PubMed.32017149.s9.e0" /><pair ddi="false" e1="DDI-PubMed.32017149.s9.e0" e2="DDI-PubMed.32017149.s9.e1" /><pair ddi="false" e1="DDI-PubMed.32017149.s9.e0" e2="DDI-PubMed.32017149.s9.e2" /><pair ddi="false" e1="DDI-PubMed.32017149.s9.e1" e2="DDI-PubMed.32017149.s9.e1" /><pair ddi="false" e1="DDI-PubMed.32017149.s9.e1" e2="DDI-PubMed.32017149.s9.e2" /></sentence><sentence text=" Safety analyses did not show local or systemic safety concerns with trifarotene up 100 µg/g, a dose twice as high as the intended market dose"><entity charOffset="69-80" id="DDI-PubMed.32017149.s10.e0" text="trifarotene" /></sentence><sentence text=" Results showed that trifarotene 50 µg/g cream is well tolerated and safe, even when applied under maximized conditions in adults and pediatric acne patients presenting with severe acne"><entity charOffset="21-32" id="DDI-PubMed.32017149.s11.e0" text="trifarotene" /></sentence><sentence text=" Daily use of trifarotene 50 µg/g cream was not associated with cardiovascular effects and did not result in drug-drug interaction in women of childbearing potential using oral contraception"><entity charOffset="14-25" id="DDI-PubMed.32017149.s12.e0" text="trifarotene" /></sentence><sentence text="" /></document>